An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
Launched by PFIZER · Jan 10, 2022
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants aged ≥18 and ≤80 with moderate to severe dermatomyositis (DM), that have completed the treatment period of a qualifying study.
- • Capable of giving signed informed consent.
- • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Exclusion Criteria:
- • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- • Participants who met discontinuation criteria at any point during the participating qualifying studies.
- • Participants with an ongoing safety event in the qualifying studies which, in the opinion of the investigator or sponsor, is an ongoing safety concern OR the participant has met safety monitoring criteria in the qualifying study that has not resolved.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Madrid, , Spain
Scottsdale, Arizona, United States
Birmingham, Alabama, United States
Jacksonville, Florida, United States
New York, New York, United States
Saint Louis, Missouri, United States
Debrecen, , Hungary
Saint Louis, Missouri, United States
New York, New York, United States
New York, New York, United States
Beverly Hills, California, United States
Fairway, Kansas, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
New York, New York, United States
New York, New York, United States
Krakow, , Poland
Philadelphia, Pennsylvania, United States
Birmingham, Alabama, United States
Kansas City, Kansas, United States
New York, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Białystok, Podlaskie, Poland
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials